Indaptus (NASDAQ: INDP) files 8-K on INDP-D101 clinical trial update

Rhea-AI Filing Summary

Indaptus Therapeutics, Inc. filed a current report to note that on September 4, 2025 it issued a press release with recent updates on its ongoing INDP-D101 clinical trial. The press release is included as Exhibit 99.1 and is incorporated by reference, meaning the detailed clinical information is contained in that separate document. The report is signed on behalf of the company by Chief Financial Officer Nir Sassi.

false 0001857044 0001857044 2025-09-04 2025-09-04 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) September 4, 2025

INDAPTUS THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

Delaware		001-40652		86-3158720
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

3 Columbus Circle 15th Floor New York, New York		10019
(Address of principal executive offices)		(Zip Code)

(646) 427-2727

(Registrant’s telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol		Name of each exchange on which registered
Common Stock, $0.01 par value		INDP		Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01. Other Events.

On September 4, 2025, Indaptus Therapeutics, Inc. issued a press release announcing recent updates for the ongoing INDP-D101 clinical trial. A copy of that press release is attached as Exhibit 99.1 hereto and is incorporated by reference herein.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.		Description
99.1		Press Release of Indaptus Therapeutics, Inc., dated September 4, 2025.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: September 4, 2025

	INDAPTUS THERAPEUTICS, INC.
	By:	/s/ Nir Sassi
	Name:	Nir Sassi
	Title:	Chief Financial Officer

FAQ

What did Indaptus Therapeutics (INDP) disclose in this 8-K?

Indaptus Therapeutics disclosed that it issued a press release on September 4, 2025 providing recent updates on its ongoing INDP-D101 clinical trial, and attached the release as Exhibit 99.1.

Which clinical trial is referenced in Indaptus Therapeutics' 8-K?

The 8-K references the company’s ongoing INDP-D101 clinical trial, for which recent updates were announced in an attached press release.

When did Indaptus Therapeutics issue the press release about INDP-D101?

The company issued the press release with updates on the INDP-D101 clinical trial on September 4, 2025.

What exhibit is included with Indaptus Therapeutics' 8-K filing?

The filing includes Exhibit 99.1, which is the press release of Indaptus Therapeutics, Inc. dated September 4, 2025, and Exhibit 104, the cover page interactive data file.

Who signed the Indaptus Therapeutics 8-K related to the INDP-D101 trial?

The 8-K was signed on behalf of Indaptus Therapeutics, Inc. by Nir Sassi, the company’s Chief Financial Officer.

On which exchange does Indaptus Therapeutics' common stock trade?

Indaptus Therapeutics’ common stock, par value $0.01 per share, trades on the Nasdaq Capital Market under the trading symbol INDP.